Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H JACKSON

Showing results (731-740 of 770) with videos related to

Pageof 77
Sort By:
Haematologica|February 9, 2019
Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patientsJohn R Jones, Niels Weinhold, Cody Ashby, et al.
British Journal of Haematology|July 14, 2020
Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trialGraham H Jackson, Charlotte Pawlyn, David A Cairns, et al.
Leukemia|June 7, 2017
Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patientsV Shah, A L Sherborne, B A Walker, et al.
Frontiers in Immunology|April 10, 2023
Vi polysaccharide and conjugated vaccines afford similar early, IgM or IgG-independent control of infection but boosting with conjugated Vi vaccines sustains the efficacy of immune responsesSiân E Jossi, Melissa Arcuri, Areej Alshayea, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2016
The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in MyelomaCharlotte Pawlyn, Martin F Kaiser, Christoph Heuck, et al.
Physical Review Letters|May 2, 2025
Dark Matter Axion Search with HAYSTAC Phase IIXiran Bai, M J Jewell, J Echevers, et al.
Plos Medicine|January 11, 2021
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trialGraham H Jackson, Charlotte Pawlyn, David A Cairns, et al.
Haematologica|June 6, 2020
Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trialGraham H Jackson, Faith E Davies, Charlotte Pawlyn, et al.
Nature|February 11, 2021
A quantum enhanced search for dark matter axionsK M Backes, D A Palken, S Al Kenany, et al.
Nature Genetics|November 29, 2011
Common variation at 3p22.1 and 7p15.3 influences multiple myeloma riskPeter Broderick, Daniel Chubb, David C Johnson, et al.
Pageof 77

Showing results (731-740 of 770) with videos related to

Sort By:
Pageof 77
Haematologica|February 9, 2019
Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patientsJohn R Jones, Niels Weinhold, Cody Ashby, et al.
British Journal of Haematology|July 14, 2020
Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trialGraham H Jackson, Charlotte Pawlyn, David A Cairns, et al.
Leukemia|June 7, 2017
Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patientsV Shah, A L Sherborne, B A Walker, et al.
Frontiers in Immunology|April 10, 2023
Vi polysaccharide and conjugated vaccines afford similar early, IgM or IgG-independent control of infection but boosting with conjugated Vi vaccines sustains the efficacy of immune responsesSiân E Jossi, Melissa Arcuri, Areej Alshayea, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2016
The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in MyelomaCharlotte Pawlyn, Martin F Kaiser, Christoph Heuck, et al.
Physical Review Letters|May 2, 2025
Dark Matter Axion Search with HAYSTAC Phase IIXiran Bai, M J Jewell, J Echevers, et al.
Plos Medicine|January 11, 2021
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trialGraham H Jackson, Charlotte Pawlyn, David A Cairns, et al.
Haematologica|June 6, 2020
Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trialGraham H Jackson, Faith E Davies, Charlotte Pawlyn, et al.
Nature|February 11, 2021
A quantum enhanced search for dark matter axionsK M Backes, D A Palken, S Al Kenany, et al.
Nature Genetics|November 29, 2011
Common variation at 3p22.1 and 7p15.3 influences multiple myeloma riskPeter Broderick, Daniel Chubb, David C Johnson, et al.
Pageof 77